Today’s PBAC outcome on Selpercatinib is a significant step forward for Australians living with medullary thyroid carcinoma (MTC).
NECA Medical Ambassador Professor Stephen Clarke says continued progress depends on a system that can keep pace with innovation.
“Australia is fortunate to have the PBS, ensuring equitable access to approved medicines. Decisions like this highlight the importance of a health system that can respond quickly to emerging evidence and ensure patients have timely access to effective therapies.”
NECA CEO Meredith Cummins welcomed the decision and its impact for patients.
“We thank the PBAC Committee and the Department of Health for this decision and the meaningful difference it will make for Australians living with MTC, providing greater certainty around access to this important treatment. Access to therapies like Selpercatinib can reduce the risk of disease progression and life-threatening deterioration for patients.”
“It is now critical that access is expedited, so patients are not left facing delays, reduced access or unnecessary financial burden while waiting for treatment, particularly where delays can impact outcomes.”
NECA will continue to advocate to ensure timely and equitable access.
